Silver Oak Securities Incorporated grew its stake in Elevance Health, Inc. (NYSE:ELV – Free Report) by 84.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,936 shares of the company’s stock after acquiring an additional 1,340 shares during the quarter. Silver Oak Securities Incorporated’s holdings in Elevance Health were worth $1,250,000 at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in ELV. West Family Investments Inc. grew its stake in Elevance Health by 62.8% in the third quarter. West Family Investments Inc. now owns 1,390 shares of the company’s stock valued at $540,000 after purchasing an additional 536 shares during the last quarter. Hantz Financial Services Inc. raised its holdings in Elevance Health by 18.8% in the third quarter. Hantz Financial Services Inc. now owns 2,438 shares of the company’s stock worth $948,000 after purchasing an additional 386 shares in the last quarter. IFG Advisory LLC raised its holdings in Elevance Health by 9.6% in the third quarter. IFG Advisory LLC now owns 433 shares of the company’s stock worth $169,000 after purchasing an additional 38 shares in the last quarter. Bellwether Advisors LLC purchased a new stake in shares of Elevance Health during the third quarter valued at about $1,223,000. Finally, Croban lifted its position in shares of Elevance Health by 8.5% during the third quarter. Croban now owns 2,222 shares of the company’s stock valued at $864,000 after buying an additional 174 shares during the last quarter. 89.24% of the stock is owned by institutional investors.
Analysts Set New Price Targets
ELV has been the topic of a number of recent analyst reports. Morgan Stanley raised their price target on shares of Elevance Health from $404.00 to $449.00 and gave the company an “equal weight” rating in a report on Thursday, October 22nd. The Goldman Sachs Group reiterated a “neutral” rating and set a $451.00 price objective on shares of Elevance Health in a research note on Friday, October 23rd. Guggenheim increased their target price on shares of Elevance Health from $460.00 to $485.00 and gave the company a “buy” rating in a research report on Thursday, October 22nd. Weiss Ratings restated a “hold (c)” rating on shares of Elevance Health in a research note on Wednesday, November 11th. Finally, UBS Group raised their target price on shares of Elevance Health from $460.00 to $523.00 and gave the company a “buy” rating in a research note on Thursday, October 22nd. Fifteen equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $456.48.
Check Out Our Latest Stock Analysis on ELV
Elevance Health Price Performance
NYSE ELV opened at $446.08 on Tuesday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.47 and a quick ratio of 1.47. The stock’s fifty day moving average price is $416.18 and its 200 day moving average price is $375.72. Elevance Health, Inc. has a 1 year low of $274.84 and a 1 year high of $450.69. The company has a market cap of $96.38 billion, a price-to-earnings ratio of 19.02, a PEG ratio of 2.05 and a beta of 0.63.
Elevance Health (NYSE:ELV – Get Free Report) last issued its earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.71 by $2.28. Elevance Health had a return on equity of 14.97% and a net margin of 2.55%. The company had revenue of $50.44 billion during the quarter, compared to analyst estimates of $49.28 billion. During the same quarter last year, the business posted $6.03 EPS. The firm’s quarterly revenue was up .7% on a year-over-year basis. As a group, equities research analysts forecast that Elevance Health, Inc. will post 29.15 earnings per share for the current year.
Elevance Health Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 18th. Stockholders of record on Friday, December 4th will be paid a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 1.5%. The ex-dividend date is Friday, December 4th. Elevance Health’s dividend payout ratio (DPR) is presently 29.34%.
Insider Activity
In related news, CFO Mark Kaye sold 10,584 shares of Elevance Health stock in a transaction dated Thursday, October 22nd. The stock was sold at an average price of $440.13, for a total transaction of $4,658,335.92. Following the completion of the sale, the chief financial officer owned 19,919 shares of the company’s stock, valued at $8,766,949.47. The trade was a 34.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Ratnakar Lavu sold 1,300 shares of Elevance Health stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $440.00, for a total value of $572,000.00. Following the sale, the executive vice president directly owned 14,849 shares of the company’s stock, valued at $6,533,560. This trade represents a 8.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.34% of the company’s stock.
Elevance Health Profile
Elevance Health, Inc. is a U.S. health benefits and services company. Formerly known as Anthem, Inc., it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans. The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.
See Also
- Five stocks we like better than Elevance Health
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.
